Rinvoq, Gazyva, and Sotyktu Emerge as Front-Runners for Lupus Care
Biologic use for systemic lupus erythematosus (SLE) is increasing, with nearly 40% of moderate-to-severe SLE patients in the U.S....
Adaptive Clinical Trial Design Adaptive Trial Design Addiction Psychiatry AI in Clinical Trials Alzheimer's Disease Article Artificial Intelligence in Clinical Trials Clinical Operations Clinical Research Clinical Trial Design Clinical Trial Operations Clinical Trial Ops Brief Clinical Trials CLINOPS WATCHDOG CNS Drug Development CNS Trials Conference Coverage CRO Consolidation Decentralized Clinical Trials Digital Health Technologies eClinical Tech News eClinical Technology EMA Executive Interviews FDA Enforcement FDA Guidance FDA Real-World Evidence FDA Regulation FDA Regulatory Strategy GCP Compliance GLP-1 Receptor Agonists Ketamine Therapy Oncology Trials Opinion Parkinson's Disease Platform Trials protocol amendments Psilocybin MDMA Psychedelic Clinical Trials PSYCH PULSE Real-World Evidence site activation Site Operations study startup Treatment-Resistant Depression
Biologic use for systemic lupus erythematosus (SLE) is increasing, with nearly 40% of moderate-to-severe SLE patients in the U.S....
Qu Biologics has completed enrollment for its RESILIENCE Study, a Phase 2 clinical trial testing QBKPN SSI, a novel...
The site team was blindsided. The patient met every inclusion and exclusion criterion, showed no red flags, and even...
Clearmind Medicine Inc. announced the successful initiation of a clinical trial site at Tel Aviv Sourasky Medical Center (TASMC)...
Windward Bio has launched its Phase 2 POLARIS clinical trial to assess the long-acting dosing of WIN378, an anti-TSLP...
PROCEPT BioRobotics announced the successful completion of three prostate cancer procedures using Aquablation therapy in an ambulatory surgery center...
In a 242-patient Phase 2b trial for cognitive impairment associated with schizophrenia (CIAS), inidascamine (formerly RL-007) failed to meet...
BriaCell Therapeutics Corp. will present two clinical data posters at the European Society for Medical Oncology (ESMO) Congress 2025...
Liminatus Pharma, a preclinical-stage biopharmaceutical company focused on cancer immunotherapy development, has partnered with Digital Offering LLC to explore...
CervoMed (NASDAQ: CRVO) will share 32-week primary endpoint results from the extension phase of its Phase 2b RewinD-LB study...